Invivyd, Inc.NASDAQ: IVVD

Invivyd to Participate in Upcoming September Investor Conferences

· Issued by Invivyd, Inc. via GlobeNewswire

Summary by 6ix AI

Invivyd, Inc., a biopharmaceutical company focused on protection from serious viral infectious diseases, said Chairman and CEO Marc W. Elia and other members of management will take part in three investor conferences in New York, NY, on September 9, 10 and 14, 2026.

Key details

  • Citi's 2026 Biopharma Back to School Conference on Wednesday, September 9, 2026 is meetings only.
  • At the 2026 Cantor Global Healthcare Conference, management will hold a fireside chat (an informal on-stage interview) on Thursday, September 10, 2026 at 9:45 AM ET, followed by investor meetings.
  • At the H.C. Wainwright 28th Annual Global Investment Conference, management will hold investor meetings before a fireside chat on Monday, September 14, 2026 at 5:00 PM ET.
  • The fireside chats will be webcast live in the investor section of Invivyd's website and archived after each event.

6ix AI wrote this summary from the release below and checked it against the release.

NEW HAVEN, Conn., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Marc W. Elia, Chairman and Chief Executive Officer, and members of company management will participate in three upcoming investor conferences:

Citi's 2026 Biopharma Back to School Conference
Wednesday, September 9, 2026 (Meetings Only)
Location: New York, NY

2026 Cantor Global Healthcare Conference
Fireside Chat: Thursday, September 10, 2026 at 9:45 AM ET (Webcast Link)
Meetings to Follow
Location: New York, NY

H.C. Wainwright 28th Annual Global Investment Conference
Fireside Chat: Monday, September 14, 2026 at 5:00 PM ET (Webcast Link)
Meetings Prior to Fireside Chat
Location: New York, NY

Live webcasts of the fireside chats will be available via the investor section of Invivyd's website at investors.invivyd.com and will be archived following each event.

The management team will host investor meetings at the conferences. Investors participating in these events who are interested in meeting with Invivyd management should contact their Citi, Cantor, or H.C. Wainwright representatives.

About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

Contacts:
Media Relations
(781) 208-0160
[email protected]

Investor Relations
(781) 208-1747
[email protected]

Invivyd, Inc. on 6ix

Story so far

Earlier from Invivyd

Later from Invivyd

All Invivyd news releases